BCL2 and diabetic kidney disease: Studies by Liu Chunyan and others found that Jinkui Shenqi Pill can downregulate the phosphorylation levels of JNK1 and Bcl-2, significantly reduce the fragments of activated caspase-3, and may protect podocytes and delay the progress of DKD through the JNK1/Bcl-2 pathway (Liu et al., 2019).